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The ﬁrst international Flemish Gynaecologic Oncol-
ogy Group (FGOG) meeting in 1997 was on tamoxifen
and the uterus. Thereafter, all the international meetings
from FGOG updated the audience biannually on the
latest developments in endocrine treatment and preven-
tion, mainly in breast, but also in other gynaecological
cancers. The 4th meeting held in 2004 was built around
the following four topics: (1) prevention of breast can-
cer; (2) the oestrogen receptor (ER) and factors interfer-
ing with anti-oestrogen activity; (3) adjuvant and
metastatic endocrine therapy; (4) hormone replacement
therapy (HRT). Over 400 delegates from 20 diﬀerent
countries attended this meeting. Each invited presenta-
tion and selected abstract for oral presentation was of-
fered an extended abstract in this supplement of
European Journal of Cancer. This accompanying Edito-
rial provides you in a nutshell the meetings highlights.2. Prevention of endocrine-responsive gynaecological
cancers
Selective oestrogen receptor modulators (SERMs),
like tamoxifen and raloxifene, have the potential to
reduce mammographic breast density [1,2]. They also
lower the incidence of breast cancer and ductal carci-
noma in situ [3–5]. Although breast cancer risk reduc-
tion with SERMs seems higher in women with high1359-6349/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
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also seen in a low breast cancer risk population, such
as in postmenopausal women with established osteopo-
rosis in the Multiple Outcomes of Raloxifene Evaluation
(MORE) trial [5]. After four years of use, continuing ral-
oxifene for another four years further reduces the breast
cancer risk by 59% as reported in the CORE trial, an
extension of the MORE trial. They studied 3510 women
continuing on raloxifene and 1703 continuing on a pla-
cebo. Less than 1% of the women taking raloxifene
developed invasive breast cancer, compared with 1.6%
of the women taking placebo [8]. Women with a proven
premalignant breast lesion such as atypical ductal
hyperplasia or lobular carcinoma in situ beneﬁtted
most from prevention and both conditions are currently
predictors for being oﬀered chemoprevention in the Uni-
ted States (US) [9,10]. Following the National Surgical
Adjuvant Breast and Bowel Project (NSABP) P1 data
[9], the American Food and Drug Administration
(FDA) registered tamoxifen for breast cancer prevention
in women with a ﬁve-year breast cancer risk of at least
1.67% according to the Gail model. Freedman and col-
leagues [11,12] have calculated that 15% of the US pop-
ulation is at risk, but that only 4.9% of all white US
women would have a positive beneﬁt/risk index for
breast cancer chemoprevention using tamoxifen.
According to a survey carried out in 2000, two years
after the FDAs approval, only, and this is probably
an overestimated number, 0.2% of white women age
40–79 years in the US without a previous history of
breast cancer were taking tamoxifen for chemopreven-
tion [12]. In women with such a high breast cancer risk,
tamoxifen would prevent or defer this disease in 1%.
According to data from the MORE trial, the estimated
number needed to treat or prevent one breast cancer
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radiol levels between 48 and 111 [6]. It is also unclear
which is best, tamoxifen or raloxifene, but this is cur-
rently being tested in the NSABP-P2 trial, which has al-
most completed the accrual of 19000 women [13].
Absence of a uterus is already one important factor in
determining diﬀerences between tamoxifen and raloxif-
ene with regard to the risk/beneﬁt ratio. Apart from
potential uterine side-eﬀects, like irregular periods, post-
menopausal vaginal bleeding, polyps, cancer and sar-
coma [14,15], other potential risks may outweigh any
beneﬁt like hot ﬂushes, pulmonary embolism, stroke,
deep vein thrombosis and eye problems such as cata-
racts [16]. Whether side-eﬀects from SERMs are diﬀer-
ent or predictable in diﬀerent breast cancer risk groups
is still unknown. Pre-existing endometrial disease and
the size of intra-uterine masses measured by ultrasonog-
raphy are risk factors for endometrial pathology on
tamoxifen [17,18] but this is currently being assessed
prospectively within ATAC (anastrazole, tamoxifen,
alone or in combination) [19], where less endometrial
side-eﬀects are expected with oral aromatase inhibitors
[20]. Risk factors for thrombo-embolic events from tam-
oxifen are less clear. Being overweight and Factor V Lei-
den and prothrombin mutations were not associated
with thrombosis, but immobilisation, fractures and
prior surgery predict for developing venous thromboem-
bolic events on tamoxifen [21]. The relative eﬀects of
tamoxifens beneﬁts and harms should also take into ac-
count that risk reduction is only seen for oestrogen
receptor (ER)-positive breast cancers and that follow-
up data like survival from breast cancer beyond those
published for P1 at the interruption of this positive trial
were never updated [5,9]. Many other questions remain
unanswered: Are breast cancers prevented permanently
or is clinical presentation only delayed; how long will
a carry-over eﬀect of tamoxifen in the preventive setting
last? According to a hypothetical calculation, in a pop-
ulation of 1000 women age 50 years with a breast cancer
risk proﬁle as in the P1-trial, 25/1000 SERM users in-
stead of 50/1000 non-SERM users will develop breast
cancer during a 15-year period. The survival beneﬁt of
tamoxifen for chemoprevention, which remains hypo-
thetical, is deﬁned by the delayed therapeutic eﬀect of
tamoxifen on tamoxifen-sensitive breast cancers that ap-
pear in the non-treated group. An estimated 10% sur-
vival beneﬁt from tamoxifen on mortality rates means
that 2–3 women in a thousand high breast cancer risk
women will not die of the disease thanks to tamoxifen.
This ﬁgure compares favourably with the eﬀect of breast
cancer screening on breast cancer mortality in this age
group and over the same time period, where between
one and two thousand women are needed to prevent
one woman from dying of breast cancer [22]. What
about newer SERMs, currently in Phase III clinical
studies for postmenopausal health, like lasofoxifene,bazedoxifene and arzoxifene? We will have to wait until
our 2006 meeting for this evidence to be reported.
The eﬀect of tamoxifen on the genital tract was the
topic of the ﬁrst international FGOG meeting in 1997;
only one oral presentation highlighted todays state of
the art on this issue [23] There is no place to screen
for asymptomatic endometrial lesions while on tam-
oxifen and baseline uterine assessment may be more
important. The molecular mechanisms of tamoxifens
carcinogenic eﬀect on the endometrium were summa-
rised [24,25]. The Dutch Tamarisk (risk of tamoxifen-
associated malignancies) study was presented [26].
Uterine sarcomas are more frequently seen (estimated
at an extra case of 1/10 000 users/year) in long-term
tamoxifen users, but this may be of less clinical rele-
vance since tamoxifen is only given for ﬁve years
[14]. This certainly is informative for trials considering
tamoxifen use for long-term prevention and if current
ongoing trials like adjuvant tamoxifen longer against
shorter (ATLAS) or adjuvant tamoxifen treatment of-
fer more (aTTom) decide more than ﬁve years should
become the standard. Tamoxifens agonistic and
antagonistic eﬀects on the female genital tract depend
on the ambient oestradiol concentration and the men-
opausal status of the patient. In postmenopausal wo-
men, tamoxifen has a potential oestrogen agonistic
eﬀect on the vaginal epithelium, the uterine myome-
trium and the endometrium, although in some women,
atrophic ﬁndings do not change on tamoxifen. Tam-
oxifen induces in most women benign cystic hyperpla-
sia of the endometrial stroma and in a few, it causes
endometrial polyps. The risk of endometrial cancer in-
creases 2–3-fold (estimated at an extra case of 1/1000
users/year) after an exposure of up to 5 years. In
asymptomatic tamoxifen users, gynaecological surveil-
lance is therefore not recommended. Any postmeno-
pausal bleeding, independent of tamoxifen use,
requires an endometrial histology. Despite its gynaeco-
logical side-eﬀects, the beneﬁts of tamoxifen in breast-
cancer treatment outweighs the risks. A non-hysterec-
tomised patient with a history of endometrial polyps
or other endometrial disease should be treated with
an oral aromatase inhibitor.
Because of long-term side-eﬀects with SERMs, the
at-risk population should have the highest possible
beneﬁt-to-risk ratio and the Gail model, which only
delineates a population with a doubling/tripling of
breast cancer risk, needs to be reconsidered [27]. Gold-
stein urged a modiﬁcation of the Gail model that also
takes other risk factors into account, such as circulating
postmenopausal oestrogens, alcohol use and breast/
bone density. He also suggested omitting a number of
previous breast biopsies because these are no longer rel-
evant in this era of core-needle/open breast biopsies fol-
lowing an abnormal screening mammogram. A further
ﬁne-tuning of the risk factors for breast cancer may be-
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the Nurses Health Study. Risk factors for breast cancer
diﬀer when divided by ER/progesterone receptor (PR)
status into four groups. Colditz and colleagues [28] re-
cently showed diﬀerent associations with age, history
of pregnancy, postmenopausal hormone use, and body
mass index (BMI) after menopause comparing oestro-
gen-sensitive with oestrogen-independent tumours.
There is clearly a need to combine risk factors to provide
a better overall determination of the breast cancer risk.
Although some risk models include genetic and fam-
ily histories, personal factors such as reproductive and
medical history should also be taken into account. How-
ever, none have incorporated personal risk factors with
a detailed genetic analysis. The discovery of the BRCA1
and BRCA2 genes has explained some of the genetic
determinants of breast cancer risk, but these genes alone
do not explain all of the familial aggregation of breast
cancer. Mutation in genes that leads to an inheritable
high sensitivity to oestrogens may also play a role [29].
Among the candidate genes are low penetrance genes
coding for proteins involved in steroidal hormone
metabolism and oestrogen receptors leading to risk
modiﬁcation, as recently suggested for the response of
high-density lipo-protein (HDL)-cholesterol to HRT
[30]. As shown in twin and family studies, bone and
breast density have a strong heritable component
[31,32]. Women with a familial history of breast cancer
also have a higher risk of breast cancer at a given level
of bone density compared with women without such a
family history of the disease. If susceptibility factors
within such families could be identiﬁed, it would be pos-
sible to identify women by their genetic proﬁle leading to
targeted breast cancer prevention and tamoxifen may
play a more important role than in carriers of mutated
BRCA genes [33]. In the meantime, risk modiﬁers for
carriers of mutated BRCA genes have been identiﬁed,
such as a lack of obesity in adolescence, physical exer-
cise, reproductive history and oral contraceptives
[34,35]. Hormone replacement is not a proven risk mod-
iﬁer, but bilateral salpingo-oophorectomy helps to re-
duce the breast cancer risk [36].
Such risk factors or risk modiﬁers should be included
in currently available risk models such as the Gail/Claus
models. Tyrer and Cuzick [37] recently developed such a
model incorporating the BRCA genes, a low penetrance
gene and other personal risk factors; following its vali-
dation, it seems to be the most consistently accurate
model for the prediction of breast cancer [38]. The Gail,
Claus and Ford models all signiﬁcantly underestimate
risk, although the accuracy of the Claus model may be
improved by adjustments for other risk factors. Once
such models are approved, the acceptability and eﬃcacy
of prevention strategies need to be validated taking the
eﬀects of such genetic risk into consideration [39]. If
strategies for prevention have a higher eﬃcacy than,for example, the long-term use of tamoxifen, it will be
easier to modify hormonal milestones in a womans life.
These milesones are age at ﬁrst pregnancy, long-term
use of hormonal contraception and substitution, long-
term use of SERMs, aromatase inhibitors, bilateral sal-
pingo-oo¨phorectomy and prevention of early age and
postmenopausal obesity [39].
As for the treatment of cancer, the psychosocial im-
pact of any prevention strategy in women at a high risk
of breast cancer should not be underestimated [40].
Should not we improve quality of life when performing
prevention? Prophylactic bilateral mastectomy, bilat-
eral salping-oophorectomy, long-term use of tamoxifen
and regular surveillance will all aﬀect the womans qual-
ity of life. Tamoxifen-related side-eﬀects are well
described with a four-year follow-up in two placebo-
controlled double-blind randomised trials investigating
tamoxifen for chemoprevention. They do not include
anxiety, psychological distress, depression or sexual dys-
functioning [41]. Only vasomotor symptoms were more
frequently reported. Raloxifene does not seem to diﬀer
from tamoxifen in this respect [42,43]. Prophylactic
breast surgery will decrease the fear of developing can-
cer, but will aﬀect body image and sexuality [44]. Bilat-
eral salpingo-oophorectomy may be more acceptable
[45]. Not only prevention, but also treatment modalities,
aﬀect quality of life. Chemotherapy compares unfavour-
able with hormonotherapy regarding quality of life is-
sues [46]. However, women will choose chemotherapy
for a proven 1% gain in survival beneﬁt. The arrival of
the oral aromatase inhibitors for the treatment and pre-
vention of breast cancer implies there will be new and
diﬀerent side-eﬀects [47]. Many of the strategies for
breast cancer prevention involve severe oestrogen depri-
vation and it is important to consider the acute and
long-term eﬀects of an early induced menopause fol-
lowed by a further lowering of circulating oestrogens
in young women (at high risk for) with breast cancer.
Musculo-skeletal events, fractures and sexual dysfunc-
tioning show how important low levels of oestrogens
are for a normal functioning in the menopause. Cuzick
presented his proposed solutions for these new side-
eﬀects [47].3. The oestrogen receptor and interfering factors
The ovarian hormones, oestrogen and progesterone
induce a complex tissue-speciﬁc response throughout
the body. Signiﬁcant progress has been made in deﬁning
the molecular mechanisms by which cells distinguish be-
tween agonists and antagonists and how some receptor
modulators (co-activators and co-repressors) can mani-
fest their actions in a cell-selective manner [48]. Predis-
positions to the risks of hormones for developing
breast and other oestrogen-related cancers may be
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environmental factors. Ligand binding to the nuclear
receptor leads to conformational changes within the
receptor and to interaction with DNA-response ele-
ments activating co-regulators. McDonnell [49] exam-
ined how we should incorporate recent advances in
our understanding of the molecular pharmacology of
oestrogens and progestins into medical practice. He also
presented evidence on how xenobiotics or environmen-
tal compounds aﬀect steroid hormone signalling and
peopless sensitivity/responsiveness to hormones. Meth-
oxyacetic acid and the commonly prescribed anticonvul-
sant, valproic acid, both short-chain fatty acids,
dramatically increase cellular sensitivity to oestrogens,
progestins, and other nuclear hormone receptor ligands
[50] and also enhance tamoxifen-mediated ER-a tran-
scriptional activity. Diﬀerent factors inﬂuence the
molecular pharmacology of ER-ligands; such as the
expression of the PR and the relative expression level
of the two ER subtypes, the diﬀerent impact of ligands
on the structure of the receptors and the ability of diﬀer-
ently conformed receptors to interact with other factors
that are needed for activity [49].
A tumours global microarray gene expression proﬁle
may be able to classify breast cancers into biological
subgroups that diﬀer with regard to patient prognosis
and response to therapy. Gruvberger and colleagues
[51] have previously shown that ER-positive and ER-
negative breast cancers have remarkably distinct gene
expression proﬁles when a hierarchical clustering of
the top 113 genes is analysed [52]. They are also able
to predict ER-protein values on a continuous scale from
the gene expression proﬁles that are switched on in ER-
positive tumours enabling a cut-oﬀ threshold for ER-
status to be set [52]. So far, no study has shown whether
this approach predicts better the response to hormonal
treatment compared with other measures which diﬀeren-
tiate between ER status, such as immunohistochemistry.
Finally, she also showed a consistent reciprocal relation-
ship (no overlap) in the expression levels of certain genes
that are important for the prediction of ER-protein and
the fraction of cells in S phase [53].
Stephen Johnston [54] showed how various growth
pathways in cancer cells cross-talk with the ER-path-
way and he showed how resistance to endocrine ther-
apy can be linked to HER-2/neu and ER co-
expression. Peptide growth factor receptors and their
associated downstream pathways appear to be inti-
mately involved in the mechanisms of acquired resist-
ance [54]. New drugs, like farnesyl transferase
inhibitors (FTI) and tyrosine kinase inhibitors (TKI)
may disrupt this cross-talk between ER and growth
factor signalling. A number of these small molecule
signal transduction inhibitors are in the early stages
of clinical development for the treatment of breast
cancer. Pre-clinical evidence suggests that these drugsmay be most eﬀective when they are used in combina-
tion with endocrine therapy due to synergy between
these two types of agents with regard to activity
[55,56]. It was also shown from laboratory data how
ER-sensitive cells adapt over time to low levels of cir-
culating oestrogens and thereby escape from oestrogen
deprivation using alternative intra-cellular signalling
pathways. Mechanisms for acquired resistance to tam-
oxifen may allow aromatase inhibitors to work. New
monoclonal antibodies, like geﬁtinib, will target alter-
native pathways delaying the development of resist-
ance to tamoxifen. This hypothesis is currently being
tested in the tamoxifen-/geﬁtinib trial for ﬁrst-line met-
astatic or locally advanced inoperable breast cancer.
Again, the question remains as to whether these ther-
apies translate into a further improvements in clinical
outcome.
Fuqua [57] stated that both ER-a coregulators and a
speciﬁc ER-a mutation are upregulated in metastatic
deposits of ER-positive breast cancer. The presence of
such an ER is a poor prognostic marker. The group gen-
erated a monoclonal antibody for the detection of ER-b
in archival, formalin-ﬁxed breast tumours and have
examined its expression using immunohistochemistry
in over 300 breast cancer patients. Coexpression of
ER-b and ER-a was found in most of the tumours.
ER-a, but not ER-b, was strongly associated with PR
expression. Although ER-a expression was positively
correlated with a good patient prognosis, ER-b expres-
sion showed a trend towards an association with aneup-
loidy and no association with tumour grade or S-phase
fraction was seen. High ER-b also predicted for a great-
er beneﬁt from tamoxifen treatment and this was
reﬂected by a better DFS and OS. ER-b therefore, seems
to be an additional and independent predictor of re-
sponse to tamoxifen treatment [58].
Recent evidence conﬁrms that both steroid hormone
receptors when considered on their own have only short-
term prognostic value [59]. When their joint expression
is considered, patients who are ER- and PR-positive
have a better outcome than those with a ER-positive/
PR-negative phenotype [59–61]. Twenty ﬁve percent of
all ER-positive breast cancers are PR-negative and this
proportion is menopausal-related. A premenopausal pa-
tient with an ER-positive breast cancer is less likely to be
PR-negative (12.8%) than after the menopause (28.1%).
A negative PR in a woman with an ER-positive breast
cancer is an independent predictor for a positive lymph
node status in women under the age of 50 years, inde-
pendent of the grade of the breast cancer, but not in
women after 50 years of age [60]. The ER-positive PR-
negative phenotype is more common after the meno-
pause and this is probably related to the lower levels
of circulating oestrogens observed after the menopause,
but may also indicate another pathway for tumour
growth, especially in premenopausal women where oes-
Table 1
Proportion of breast cancers being HER-2/neu-positive by age and PR
in women with an ER-positive breast cancer
HER-2/neu 2+/3+ (%) <50 years >50 years
ER+PR+ 14.7% 9.9%
ER+PR 23.8% 20.5%
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cancer which is PR-negative is more likely to be HER-
2/neu-positive compared with an ER-positive breast
cancer that also expresses PR (Table 1) [62]. This may
explain resistance to tamoxifen in women with an ER-
positive breast cancer when PR is not expressed [63].
On hormonal therapy, disease-free curves between the
phenotypes ER+PR+ and ER+PR widen referring to
a better response to hormone therapy in cases of an
ER+PR+ breast cancer [59]. Dowsett [55] also presented
evidence that the ER-positive/PR-negative phenotype of
breast cancer beneﬁts more from anastrazole than from
tamoxifen therapy.
Many other molecules are involved in the biology of
breast cancer and studied for their potential as predic-
tive markers for hormonal therapy [64–66]. Overexpres-
sion of cyclin E or its low molecular weight forms is
associated with a poor prognosis and may also explain
resistance to anti-oestrogens [64]. They are overex-
pressed in 25% of breast cancers, where two-thirds were
ER-positive. These molecules bypass the inhibitory ef-
fects of p21 and p27 induced by anti-oestrogen treat-
ment and may thereby lead to de novo or acquired
resistance to anti-oestrogens. Results from the clinic
are awaited. Further studies are also warranted to ex-
plain the underlying resistance to endocrine therapy
when urokinase plasminogen activation: plasminogen
activator inhibitor-I (uPA:PAI-I) levels are high [65].
The levels of evidence for most molecular markers are
currently being studied and these markers are still
unsuitable to make individual patient treatment
choices.
Gene microarrays have been successfully used to
classify breast cancers into subtypes with speciﬁc gene
expression proﬁles and to evaluate prognosis [67,68].
Reverse transcriptase-polymerase chain reaction (RT-
PCR) has also been used to evaluate the expression
of multiple genes in archival tissue. Berns and
colleagues [68] used glass arrays with approximately
18 000 spotted human cDNAs to identify a gene
expression pattern that predicts the type of response
to anti-oestrogen therapy. These microarrays have
identiﬁed and validated a set of classiﬁer genes that
can distinguish primary breast tumours from patients
who responded and who did not respond to anti-
oestrogen treatment [69]. However, as yet, gene mic-
roarrays for prognostic or predictive purposes are stillexperimental. Several groups are currently exploring
the possibility of using these prognostic gene expres-
sion proﬁles to guide adjuvant therapy, especially to
identify those who may not need this therapy, i.e. the
lymph node-negative patients. Proteomic technologies,
the study of the complete set of proteins expressed in
a cell, are in development and will also be used to pre-
dict response. Serial biopsies, that compare the protein
proﬁle before and after hormonal therapy, may allow
us to determine particular protein proﬁles that predict
for ultimate clinical outcomes [70].4. Adjuvant therapy
What is the ideal hormone therapy for a premeno-
pausal woman with an ER-positive breast cancer? Can
we leave out chemotherapy? Is (temporary) amenor-
rhoea better; is there a place for aromatase-inhibitors
or can we continue to use tamoxifen? Where polychem-
otherapy is the only option for women with an ER-
negative breast cancer, polychemotherapy, tamoxifen,
and ovarian ablation all reduce the risk of recurrence
and death from ER-positive breast cancer by at least a
quarter [71]. The meeting recognised that tamoxifen is
always needed, either alone or in combination with the
other modalities: chemotherapy or ovarian ablation.
There are enough data to support this assumption and
the Early Breast Cancer Trialists Cooperative Group
(EBCTCG) has conﬁrmed this in their latest published
overview analysis, which was updated during this sym-
posium: Tamoxifen is better than no tamoxifen and its
combination with ovarian ablation is better than ovar-
ian ablation alone, independent of whether chemother-
apy was given [71,72]. The FGOG meeting in Brussels
asked the following two questions:
(1) Do we still need to give adjuvant chemotherapy?
Today, almost all premenopausal women with high-risk,
ER-positive breast cancer receive polychemotherapy fol-
lowed by hormone therapy. Endocrine therapy alone
with suppression of ovarian function plus tamoxifen
may be suﬃcient to achieve the same outcomes as chem-
otherapy, especially for patients at a low risk of recur-
rent disease. The ablation or suppression of ovarian
function was equivalent to chemotherapy in at least
eight randomised trials [73]. Among the many studies
that have compared adjuvant chemotherapy with endo-
crine therapies, one of the largest has been the Interna-
tional Breast Cancer Study Group (IBCSG) [74] and
Austrian Breast and Colorectal Cancer Study Group
(ABCSG) Trial 5 [75,76], which yielded similar results
for LHRH alone and better results for LHRH plus tam-
oxifen than with chemotherapy alone. However, despite
the fact that these trials favour the use of combined hor-
monotherapy this does not justify the systematic
replacement of adjuvant chemotherapy followed by hor-
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in all premenopausal patients with endocrine-responsive
tumours. We lack data on the eﬃcacy of ovarian abla-
tion plus tamoxifen compared with regimens shown to
be superior to 6X cyclophosphamide, methotrexate, 5-
ﬂuorouracil (CMF) or 4X doxorubicin, cyclophospha-
mide (AC). The ideal adjuvant hormone therapy will
have to be compared with the best available combina-
tion of chemotherapy sequentially followed by the best
hormone therapy. This may be tamoxifen, or ovarian
suppression plus tamoxifen or ovarian suppression plus
an aromatase inhibitor. The answer to the question for
the need of adjuvant chemotherapy is currently being
investigated in the Premenopausal Endocrine Respon-
sive Chemotherapy (PERCHE) trial, which compares
suppression of ovarian function plus chemotherapy fol-
lowed by tamoxifen or exemestane versus suppression of
ovarian function and tamoxifen or exemestane without
chemotherapy for patients with ER-positive tumours
[77].
(2) Do we need to add ovarian ablation to tamoxifen
or to chemotherapy plus tamoxifen? The question is an
old one [78], but we still do not have the answer. Several
studies like the ZIPP-trial have compared the additional
eﬀect of ovarian ablation to tamoxifen, but, unfortu-
nately, no decent published data are available. A
surrogate marker for ovarian suppression is post-
chemotherapy amenorrhoea. Whether chemotherapy-
induced amenorrhoea has a prognostic eﬀect remains
unclear [76], as prospective studies do not exist. Some
retrospective analyses show that women who continue
to have menses have less beneﬁt from chemotherapy
with regard to a reduced risk of recurrence and death,
especially if they are aged less than 40 years and node-
positive [79–81]. The recently published data from the
IBCSG also show that only young women may beneﬁt
from post-chemotherapy ovarian suppression, but do
not answer the question of whether this is also the case
if tamoxifen is added to CMF – the chemotherapy reg-
imen used in this study [74]. Pooling all retrospective
data, more evidence is compatible with an additional
adjuvant eﬀect of amenorrhoea after chemotherapy,
particularly in women aged < 40 years but level 1 evi-
dence is lacking. We also agree that the time has come
to examine whether an aromatase inhibitor will prove
to be a superior alternative, because the results of recent
trials indicate that complete suppression of oestrogen
production for ﬁve years may be a better strategy than
blocking its action at the receptor level [82,83]. This
question of ovarian suppression and aromatase inhibi-
tors is now being addressed by the global Suppression
of Ovarian Function Trial (SOFT; coordinated by the
IBCSG on behalf of the Breast International Group
(BIG) and the North American Breast Cancer Inter-
group) [77]. SOFT compares tamoxifen alone versus
suppression of ovarian function (by either the Gonadot-rophin-releasing hormone (Gn-RH) analogue triptorelin
or bilateral oophorectomy or ovarian irradiation) plus
tamoxifen versus suppression of ovarian function plus
exemestane (a steroidal aromatase inhibitor) for patients
with hormone receptor-positive tumours who remain
premenopausal after adjuvant chemotherapy or for
whom tamoxifen alone is considered a reasonable treat-
ment option. The complementary Tamoxifen and
Exemestane Trial (TEXT) compares the Gn-RH ana-
logue triptorelin, plus tamoxifen versus triptorelin plus
exemestane for patients who receive the Gn-RH ana-
logue, with or without chemotherapy from the start of
their adjuvant therapy programme (77). Thus, the roles
of ovarian function suppression and of an aromatase
inhibitor are being prospectively studied in the adjuvant
setting for premenopausal patients with endocrine-
responsive breast cancer.
Postmenopausal women with a lymph node-negative
breast cancer expressing high levels of ER have no sur-
vival advantage above 1% from adding chemotherapy to
tamoxifen [84]. Those ﬁt enough for chemotherapy and
at a high risk of relapse (node-positive disease) do gain
some beneﬁt from CMF according to some [85], but
not all studies [86]; beneﬁt of chemotherapy plus tam-
oxifen versus tamoxifen alone has been reported if
chemotherapy contains an anthracycline [87] or a taxane
[88,89]. Within these trials, some higher risk subgroups,
such as those with N2a lesions [88], or women with an
ER-positive breast cancer, did not necessarily beneﬁt
from the added taxane [89,90]. If tamoxifen is started
after completion of chemotherapy, chemotherapy is
more eﬃcient because tamoxifen seems to antagonise
chemotherapy [87]; by contrast, there is no need to wait
until the end of radiotherapy before starting tamoxifen.
Some patients with an ER-positive tumour and also
expressing HER-2/neu may not beneﬁt at all from adju-
vant tamoxifen, as has been suggested from results in a
neoadjuvant clinical trial comparing tamoxifen with
letrozole in postmenopausal women [91]. So far, the true
predictive value of HER-2/neu can only be estimated
from prospective randomised clinical trials [92,93]. A
lot of as yet unknown data from adjuvant trials compar-
ing tamoxifen with these three oral aromatase inhibitors
are still awaited. All three oral aromatase inhibitors oﬀer
the clinician more choices when deciding the adjuvant
hormone therapy in postmenopausal breast cancer pa-
tients [82,94–96]. From the eﬃcacy viewpoint, only data
on disease-free but not overall survival are available. In
the adjuvant setting, ﬁve years of anastrazole is cur-
rently the only aromatase inhibitor to have proven supe-
rior eﬃcacy over ﬁve years of tamoxifen [82]. There is no
place for combined anastrazole and tamoxifen treatment
[82]. Statistically signiﬁcant reductions in serum letroz-
ole and anastrazole levels of 37% and 27%, respectively,
have been observed in patients receiving these drugs in
combination with tamoxifen. A second possible expla-
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tion of tamoxifen with anastrazole or letrozole is that
the elimination of 99% of oestrogens from the body with
oral aromatase inhibitors causes the partial oestrogen
agonistic eﬀects of tamoxifen to become apparent.
As said before, the subgroup of ER-positive breast
cancer patients not expressing PR may beneﬁt more
from anastrazole than from tamoxifen compared with
those expressing PR [94]. Ferno and colleagues [97] al-
ready found prolonged tamoxifen therapy for ﬁve years
instead of two years was beneﬁcial for patients with ER-
positive and PR-positive breast cancer, whereas three
extra years of tamoxifen had little or no eﬀect for pa-
tients with ER-positive, but PR-negative tumours. Fur-
thermore, recent evidence shows that following two
years of tamoxifen treatment, switching to exemestane
is superior to continued tamoxifen in postmenopausal
women with an ER-positive breast cancer. Also, women
with a lower risk of disease recurrence and independent
of the PR-status seem to beneﬁt. This conﬁrms previous
data recently presented for the switch to anastrazole
after 2 years taking tamoxifen [96,98]. Data for letrozole
against tamoxifen from baseline or following two years
of tamoxifen and vice versa are awaited from the BIG-
98 trial, but starting letrozole after ﬁve years of tamoxi-
fen is better than stopping tamoxifen with a small
survival advantage in node-positive patients, as presented
during the last American Society of Clinical Oncologists
(ASCO) meeting [95,99]. Letrozole is the ﬁrst and only
treatment to achieve a signiﬁcant disease-free survival
(DFS) beneﬁt in the extended adjuvant setting after
early use of adjuvant tamoxifen. However, there was
no survival beneﬁt in node-negative patients, the fol-
low-up is short and the optimal duration of use of
letrozole after ﬁve years of tamoxifen is still unknown
[95,100]. In a trial of extended adjuvant therapy, adverse
events were reported more frequently following letrozole
treatment than placebo including hot ﬂushes, arthralgia,
myalgia and arthritis.
So far, only tamoxifen, toremifene and anastrazole are
approved for adjuvant therapy of breast cancer, but oth-
ers will follow. Some subgroups may do better with an
oral aromatase inhibitor frombaseline, or after twoorﬁve
years of tamoxifen, but speciﬁc guidelines have not yet
been drawn. New treatments also imply new side-eﬀects
and some will be more speciﬁc for one compound than
for another. The steroidal structure of exemestane, and
especially its 17-hydro-metabolite may induce less bone
loss than the non-steroidal aromatase inhibitor [101].
However, Lonning and colleagues [102] showed that after
two years of therapy, compared with placebo, exemes-
tane, like anastrazole [101], also increases bone loss, espe-
cially at the femoral neck, but not in the spine.
Neoadjuvant hormone therapy can reduce the tu-
mour volume making inoperable tumours operable or
enabling patients (who would have required a mastec-tomy) to undergo breast-conserving surgery
[91,103,104]. The biological diﬀerences between tamoxi-
fen and aromatase inhibitors with regard to their eﬀect
on proliferation [105] are reﬂected in the clinic. Re-
sponses with each of the available aromatase inhibitors
appeared greater than those with tamoxifen, with higher
rates of conversion from mastectomy to breast-conserv-
ing surgery. Recent data from Edinburgh conﬁrm that
anastrazole is also eﬀective in the neoadjuvant setting
in HER-2/neu-overexpressors [103]. Results from direct
comparisons of anastrazole and letrozole are underway
regarding quality of life and side-eﬀects, ability to down-
regulate proliferation, PR expression, eﬀects on lipids,
clotting and bone metabolism.5. Metastatic cancer
The combination of tamoxifen and suppression of
ovarian function remains the best 1st line therapy for
premenopausal patients with an ER-positive metastatic
breast cancer [106]. We do not know whether substitu-
tion of tamoxifen by an aromatase inhibitor in this situ-
ation is better. We do know that the substitution of
tamoxifen by anastrozole as second-line therapy in com-
bination with castration, still produces a signiﬁcant clin-
ical response [107]. For postmenopausal women, recent
clinical trials have shown that all three third-generation
aromatase inhibitors present signiﬁcant eﬃcacy advan-
tages over traditional tamoxifen in ﬁrst-line [108–111]
and over progestins or aminoglutethimide for second-
line after tamoxifen [106]. Starting with an oral aroma-
tase inhibitor instead of starting with tamoxifen will
prolong the total duration of endocrine therapy before
chemotherapy has to be used and this improves the pa-
tients quality of life. Two ﬁrst-line phase III trials of
letrozole versus tamoxifen [108] and anastrazole versus
tamoxifen [111] showed the aromatase inhibitors to be
superior to tamoxifen in short-term survival measures
only. These data suggest that aromatase inhibitors
may replace tamoxifen in the ﬁrst-line hormonal man-
agement of this disease in postmenopausal women.
Comparative trials of anastrozole versus letrozole [112]
or anastrazole versus exemestane [113] for second-line
hormonal therapy in metastatic breast cancer have also
been performed. In an open label trial [112], letrozole
was found to be superior to anastrazole with regard to
the overall response rate, but the other clinical endpoints
like time to progression which was the primary endpoint
were not diﬀerent.
Tumours progressing on tamoxifen remain sensitive
to second-line therapy with oral aromatase inhibitors.
Although tumours take a longer time to progress on
aromatase inhibitors, once they do, they are less respon-
sive to tamoxifen [108,114]. However, recent data
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after relapse on an aromatase inhibitor [115].
Several clinical trials are ongoing to determine
whether the addition of monoclonal antibodies, like
trastuzumab, or ErbB-speciﬁc TKIs, like Iressa, or
inhibitors of downstream signal transducers, like FTIs,
to anti-hormone agent will also provide breast cancer
patients with beneﬁts in clinical practice [116].
Fulvestrant is the ﬁrst of a new type of ER-antagonist
that downregulates the ER and PR. It is devoid of the
partial agonist properties of tamoxifen when tested in
laboratory models. This unique mode of action means
that it is important that fulvestrant is placed optimally
within the sequence of endocrine therapies to ensure that
patients gain maximum beneﬁt [117]. Fulvestrant has
shown eﬃcacy in patients heavily pretreated with prior
endocrine therapy, such as tamoxifen or anastrozole in
postmenopausal women with advanced breast cancer
[118]. Recently published data also conﬁrms its activity
in the ﬁrst-line [119]. After progression on fulvestrant,
subsequent endocrine treatments can still produce re-
sponses, demonstrating that fulvestrant does not lead
to cross-resistance with other endocrine therapies
[120]. Other hormonal agents, like the newer SERMs,
are being compared with tamoxifen for their eﬃcacy in
metastatic breast cancer [121].
In metastatic endometrial cancer, although no proven
beneﬁt in the adjuvant setting, progestogens have been
the cornerstone of the hormonal treatment of recur-
rent, advanced or metastatic endometrial cancer [122].
Like in breast cancer, response to progestogens is related
to PR-status. The ideal dose is 200 mg medroxyproges-
terone acetate which is equally eﬀective with less side-
eﬀects than the 1 g dose [123]. Tamoxifen also has a small
beneﬁt in the metastatic setting of endometrial cancer. A
regimen of alternating megestrol acetate and tamoxifen
is active in treating endometrial cancer and may result
in a prolonged complete response in some patients
[124,125]. Locally-released levonorgestrel, that is cost-
eﬀective when compared with hysterectomy for menor-
rhagia [126], has also been reported to be eﬀective in
grade I endometrial cancers and premalignant endome-
trial conditions, but only data from case reports are
available [127–129]. This should not become standard
practice, but may be an option for inoperable obese wo-
men or those wanting to preserve fertility [130]. Other
agents, like the newer SERMs such as arzoxifene [131],
and aromatase inhibitors, like exemestane, are being
or will be tested in women with advanced or recurrent
endometrial cancer. Endometrial stromal sarcomas
and uterine adenosarcomas [132] contain high levels of
steroid receptors; c-erbB-2 is also expressed, but only
in a quarter of undiﬀerentiated uterine sarcomas [133].
Letrozole at a daily dose of 2.5 mg has been shown to
be eﬀective in low-grade endometrial stromal sarcomas
with positive oestrogen receptors [134]. Aromataseinhibitors, like letrozole, also show some activity and
limited toxicity in relapsed ovarian cancer patients; there
is no association between response and hormonal recep-
tor expression, so the underlying mechanisms of letroz-
ole action have still to be elucidated [135].6. Hormone replacement therapy
Women on continuous oestradiol valerate for second-
ary prevention of cardiovascular disease in the ESPIRIT
Trial had a large rate of non-compliance because of vag-
inal bleeding in 57%. The rate of atypical hyperplasia in
the group of bleeders was only 4% which means that
bleeding preceeded the endometrial premalignant
abnormalities [136]. Women on HRT for the menopause
do risk more gynaecological interventions than those on
placebo [137] or raloxifene [138,139]. Low doses of oes-
trogens such as oestradiol 1 mg, conjugated equine oes-
trogens 0.3 mg orally per day or transdermally applied
oestradiol 25 lg per 24 h have been shown to be eﬀective
for the treatment of vasomotor symptoms and for pre-
vention of bone loss. Little long-term data on endome-
trial safety are available, the longest study has only
two years of follow-up [140]. Levonorgestrel-intrauter-
ine device (LNG-IUD) appears an eﬀective method of
counteracting the stimulatory eﬀect of oestrogen on
the endometrium. Long-term endometrial and breast
safety with the combination of systemic oestrogens
and local LNG-IUD are promising, but require longer
follow-up [141]. In addition, data on the endometrial
safety of quarterly administration of progestins are
missing [142]. In our opinion, progestogens are always
required for endometrial protection, even if one consid-
ers low doses of oestrogens for postmenopausal health
[143]. Another solution may be fulvestrant which may
be protective against oestrogen stimulated growth of
the endometrium, at least in preclinical models. Fulves-
trant at a dose of 250 mg signiﬁcantly inhibited the oes-
trogen-stimulated thickening of the endometrium
compared with placebo [144]. Tibolone, a selective oes-
trogen enzyme modulator (SEEM), or now called selec-
tive tissue oestrogenic activity regulator (STEAR), is a
synthetic steroid with oestrogenic, androgenic and pro-
gestogenic properties, which has been successfully used
as an alternative to oestrogen replacement therapy in
several countries [145,146]. Vaginal bleeding rates on
tibolone are higher than placebo, but lower than
HRT, especially if taken early in the menopause. One
of its outstanding features is that it does not stimulate
endometrial proliferation in the short-term, although
endometrial polyps and cancers have been reported in
long-term tibolone users [147]. The THEBES trial cur-
rently evaluates tibolones long-term endometrial eﬀects.
It has been estimated that all types of HRT, including
tibolone, increase the risk of breast cancer within 1–2
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risk is related to the duration of HRT use, but not to
the age at which HRT is started and this excess risk dis-
appears within about ﬁve years of stopping. Approxi-
mately 32 in every 1000 women aged 50–65 years not
using HRT have breast cancer diagnosed over a 15–20
year period. In those using oestrogen-only, data are con-
troversial. In the Womens Health Initiative (WHI), 10
739 women were exposed to either CEE or placebo. Esti-
mated Hazard Ratios (95% Conﬁdence Intervals) for
CEE vs placebo for breast cancer was 0.77 (0.59–1.01)
with data from 218 cases. This translates into a possible
reduction of breast cancer [149]. These data were not
conﬁrmed in the Million Womens Study (MWS) where
ﬁve years of oestrogen use was proposed to lead to 1.5
extra cases of breast cancer in 1000 and approximately
ﬁve extra cases in 1000 after 10 years use [151]. Diﬀer-
ences between both studies have been explained by dif-
ferences in proportions of women with a high body
mass index. Therefore, women with a low body mass in-
dex may also have an elevated risk for breast cancer if
they are exposed to oestrogens although this risk ap-
pears to be small.
Using oestrogen and progestogen combined HRT for
ﬁve years, breast cancer was diagnosed in six extra cases
in 1000 and 19 extra cases in 1000 after 10 years use
[150]. For E-P HRT, WHI [150] and MWS [151] agree
on an increased breast cancer risk. Such tumours are
not necessarily associated with better patients prog-
noses [152,153]. Tibolone increases the risk of breast
cancer, but to a lesser extent than combined E–P HRT
[151,154]. Women already treated for breast cancer
should not be exposed to HRT. In the HABITS trial,
there was an increase in risk in those breast cancer pa-
tients on HRT [155]. The safety of tibolone in this set-
ting is currently being tested. The LIBERATE trial
continues because preliminary evidence on a small num-
ber of new or relapsed cases in this study suggests it is
safe in this high-risk population (at least over the
short-term) [154]. During this meeting, we have also seen
data presented that HRT may aﬀect screen-detected
breast cancers diﬀerently than non-screen-detected
cancers [156].
We should also not forget the advantages of HRT
during the menopause [157,158]. Long term use of E–P
HRT is associated with a decreased risk of osteoporotic
fractures and colorectal cancer [158]. However, colorec-
tal cancers in women who took E-P HRT were diag-
nosed at a more advanced stage than those in women
who took placebo.
Rozenberg [159] reviewed existing literature on the
menopausal management of patients treated for breast
cancer. He stressed the need for better, more eﬃcient,
non-hormonal alternatives for menopausal women with
a breast cancer because HRT is not safe. Phyto-oestro-
gens, marketed for use by postmenopausal women asnatural and safe alternatives to HRT, are not eﬀective
for menopausal vasomotor symptoms [160]. The beneﬁ-
cial eﬀects of phyto-oestrogens on bone are promising,
but still have to be conﬁrmed [161]. A diet high in isoﬂ-
avonoids (soy) is associated with a lower endometrial
cancer risk in Asian populations [162], but studies
regarding the important role of dietary intake of
phyto-oestrogens and breast cancer risk in European
populations remain controversial [163,164]. Phyto-oes-
trogens have also not been tested for their safety. Do
they aﬀect growth of pre-existing breast or endometrial
tumours? Cell culture studies report both the oestro-
genic stimulation of ER-positive breast cancer cell lines
and the antagonism of tamoxifen activity at physiologi-
cal phyto-oestrogen concentrations. A recent report
from a breast cancer chemoprevention study suggests
red clover does not increase breast density [165]. Possi-
ble interaction with other non-hormonal alternatives
for menopausal symptoms in breast cancer patients on
tamoxifen have also to be considered as was recently
done for paroxetine [166]. Clonidine, venlafaxine, par-
oxetine, ﬂuoxetine and gabapentin are non-hormonal
agents that have demonstrated eﬃcacy in small control-
led and uncontrolled trials in reducing hot ﬂashes. These
should be considered in patients who are unwilling or
unable to take hormonal therapies but clearly are less
eﬀective than oestrogens [167].7. Others
Pregnancy aﬀects breast cancer risk, diagnosis and
treatment. Breast cancer also has an impact on subse-
quent pregnancy [168]. Young age at ﬁrst full-term preg-
nancy is protective, but miscarriage on its own has no
eﬀect [169]. Breast cancer is not more frequently diag-
nosed during pregnancy, but pregnancy implies a
short-term increase in the risk of breast cancer which
protects thereafter, although this protective eﬀect is
age-related. Pregnancy delays the diagnosis of breast
cancer, but should not interfere with surgery and some
types of chemotherapy are justiﬁed. Prognosis is
thought not to be signiﬁcantly diﬀerent from non-
pregnancy-associated breast cancer, except in cases
where a delay in diagnosis is associated with more ad-
vanced disease. Prognostic markers are not diﬀerently
expressed, although numbers are limited. Treatment is
similar to non-pregnant cases, with the exception of
radiotherapy, which is contraindicated throughout preg-
nancy. Chemotherapy is contraindicated during the ﬁrst
trimester and last couple of weeks of pregnancy. Anti-
hormone therapy can easily be delayed until after full-
term pregnancy. Few breast cancer survivors go on to
conceive, but those who do have no worse breast cancer
or pregnancy outcomes. The superior survival for those
conceiving after treatment for breast cancer may merely
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consistent with an antitumour eﬀect of the pregnancy.References
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